Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 130 publications
Real-world outcomes of chemoimmunotherapy in advanced biliary tract cancer: a multicenter study with a propensity-matched historical cohort.
Journal: ESMO real world data and digital oncology
Published: August 22, 2026
DESTINY-Gastric05 phase III trial of first-line trastuzumab deruxtecan, chemotherapy, and pembrolizumab in HER2-positive gastric or gastroesophageal junction cancer.
Journal: ESMO gastrointestinal oncology
Published: April 17, 2026
Role of dynamic ctDNA monitoring in cervical and anal epidermoid carcinomas under curative chemoradiation.
Journal: Clinics (Sao Paulo, Brazil)
Published: March 09, 2026
Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 study.
Journal: Breast cancer research and treatment
Published: November 22, 2025
Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123.
Journal: NPJ breast cancer
Published: November 02, 2025
Preoperative MRI assessment of rectal cancer for predicting metastasis-free survival-a post hoc analysis of a randomized controlled clinical trial.
Journal: European radiology
Published: June 17, 2025
Oral Cyclophosphamide for Patients With Metastatic Castration-Resistant Prostate Cancer in a Scenario of Limited Health Care Resources.
Journal: JCO global oncology
Published: January 30, 2025
Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real/GBECAM 0123 study.
Journal: Breast (Edinburgh, Scotland)
Published: January 15, 2025
Modern therapeutic approaches in cholangiocarcinoma: A narrative review of key biomarkers and clinical trials.
Journal: Translational oncology
Published: January 06, 2025
Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study.
Journal: Breast cancer research and treatment
Published: November 12, 2024
Last Updated: 09/26/2026